506 related articles for article (PubMed ID: 10346670)
1. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
Heymann LA
Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
[No Abstract] [Full Text] [Related]
2. American beauty: an analytical view of the past and current effectiveness of cosmetic safety regulations and future direction.
Termini RB; Tressler L
Food Drug Law J; 2008; 63(1):257-74. PubMed ID: 18561461
[No Abstract] [Full Text] [Related]
3. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
Dudzinski DM
Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
[No Abstract] [Full Text] [Related]
4. Unapproved drugs in the United States and the Food and Drug Administration.
Nasr A; Lauterio TJ; Davis MW
Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
[TBL] [Abstract][Full Text] [Related]
5. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
6. FDA law enforcement: critical to product safety.
Rados C
FDA Consum; 2006; 40(1):21-7. PubMed ID: 16528823
[No Abstract] [Full Text] [Related]
7. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
8. Regulation of cosmetics that are also drugs.
Greff JA
Food Drug Law J; 1996; 51(2):243-72. PubMed ID: 11820201
[No Abstract] [Full Text] [Related]
9. We really need to talk: adapting FDA processes to rapid change.
Lykken S
Food Drug Law J; 2013; 68(4):357-99, i. PubMed ID: 24552079
[TBL] [Abstract][Full Text] [Related]
10. Reading our lips: the history of lipstick regulation in Western seats of power.
Schaffer SE
Food Drug Law J; 2007; 62(1):165-225. PubMed ID: 17444030
[No Abstract] [Full Text] [Related]
11. Protecting the consumer from getting burned: the FDA, the administrative process, and the tentative final monograph on over-the-counter sunscreens.
Jones PR
Am J Law Med; 1994; 20(3):317-35. PubMed ID: 7702077
[No Abstract] [Full Text] [Related]
12. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
13. Scientific and legal viability of follow-on protein drugs.
Dudzinski DM; Kesselheim AS
N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
[No Abstract] [Full Text] [Related]
14. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
Patsner B
Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
[No Abstract] [Full Text] [Related]
15. Sure cure: public policy on drug efficacy before 1962.
Swann JP
Publ Am Inst Hist Pharm; 1997; 16():223-61. PubMed ID: 11619897
[No Abstract] [Full Text] [Related]
16. Teaching clinicians about drugs--50 years later, whose job is it?
Avorn J
N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
[No Abstract] [Full Text] [Related]
17. FDA regulatory compliance reconsidered.
Tobias C
Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
[No Abstract] [Full Text] [Related]
18. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
19. Off-label uses of drugs and medical devices: should the FDA crack down?
Margolis RE
Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289
[No Abstract] [Full Text] [Related]
20. American roulette--contaminated dietary supplements.
Cohen PA
N Engl J Med; 2009 Oct; 361(16):1523-5. PubMed ID: 19812394
[No Abstract] [Full Text] [Related]
[Next] [New Search]
